

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)



(10) International Publication Number
WO 2023/194222 A1

(51) International Patent Classification:

A61K 31/513 (2006.01) *A61K 31/381* (2006.01)
A61K 45/06 (2006.01) *A61K 31/422* (2006.01)
A61P 7/02 (2006.01) *A61K 31/427* (2006.01)
A61P 9/10 (2006.01)

(21) International Application Number:

PCT/EP2023/058464

(22) International Filing Date:

31 March 2023 (31.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/327,684 05 April 2022 (05.04.2022) US
22171543.6 04 May 2022 (04.05.2022) EP

(71) Applicants: **SOCPIA SCIENCES SANTÉ HUMAINES S.E.C.** [CA/CA]; A/S Transfertech Sherbrooke, 35, rue Radisson / Bureau 200, Sherbrooke, Québec J1L 1E2 (CA). **BAYER AKTIENGESSELLSCHAFT** [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE).

(72) Inventors: **D'ORLÉANS-JUSTE, Pedro**; c/o SOCPIA SCIENCES SANTÉ ET HUMAINES S.E.C., A/S Transfertech Sherbrooke, 35, rue Radisson / Bureau 200, Sherbrooke, Québec J1L 1E2 (CA). **LAPOINTE, Catherine**; c/o SOCPIA SCIENCES SANTÉ ET HUMAINES S.E.C., A/S Transfertech Sherbrooke, 35, rue Radisson / Bureau 200, Sherbrooke, Québec J1L 1E2 (CA). **HEITMEIER, Stefan**; Am Wasserturm 56, 42489 Wülfrath (DE). **TINEL, Hanna**; In der Beek 16, 42113 Wuppertal (DE). **DAY, Robert**; c/o SOCPIA SCIENCES SANTÉ ET HUMAINES S.E.C., A/S Transfertech Sherbrooke, 35, rue Radisson / Bureau 200, Sherbrooke, Québec J1L 1E2 (CA). **VINCENT, Laurence**; c/o SOCPIA SCIENCES SANTÉ ET HUMAINES S.E.C., A/S Transfertech Sherbrooke, 35, rue Radisson / Bureau 200, Sherbrooke, Québec J1L 1E2 (CA). **SCHWERTANI, Adel**; c/o SOCPIA SCIENCES SANTÉ ET HUMAINES S.E.C., A/S Transfertech Sherbrooke, 35, rue Radisson / Bureau 200, Sherbrooke, Québec J1L 1E2 (CA). **ZIMMERMANN, Katja**; Bockumer Str. 370, 40489 Düsseldorf (DE). **TERSTEEGEN, Adrian**; Rübzahlweg 8, 42111 Wuppertal (DE).

(74) Agent: **BIP PATENTS**; c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50, 40789 Monheim am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERS

(57) Abstract: The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

WO 2023/194222 A1